Skip to Main Content

A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Conditions

Diseases of the Lung

Phase III

What is the purpose of this trial?

Brief Summary:

The main objective is to assess long term tolerability and safety of treatment with oral nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) who have complete (and did not prematurely discontinue trial medication in) the phase III parent trial, INBUILD® (trial 1199.247).

  • Trial with
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • Start Date
    03/26/2019
  • End Date
    08/30/2022
Trial Image

For more information about this study, contact:

Maksym Minasyan

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/23/2019
  • Study HIC
    #2000025055